Pharma Business - January 15, 2014
Symrise has increased its shareholding in Probi to 30.03%
Symrise has increased its shareholding in Probi to 30.03% which gives rise to an obligation to launch a mandatory public offer. Probi has been informed that on 10 January 2014 Symrise AG (“Symrise”) acquired 11,010 shares in Probi AB (publ) (“Probi” or “the company”), which is listed on Nasdaq OMX Stockholm, whereby Symrise holds 2,812,505 […]
